EMERGENT BIOSOLUTIONS INC (EBS)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for EBS
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| EBS | Director | 77 | ["NIAID/NIH Scientist Emeritus", "Member of the National Academy of Medicine since 2002", "Interim Director of the NIH Office of Research Support and Compliance", "Chief of the Cytokine Biology Section in the Division of Intramural Research, NIAID", "Chief of the Division of Cytokine Biology in CBER", "Ph.D. in biochemistry from Johns Hopkins University", "B.S. degree, cum laude, in chemistry from Rensselaer Polytechnic Institute", "President of the International Society for Interferon and Cytokine Research", "Served as Principal Deputy Director of the Center for Cancer Research at NCI", "Inducted into the Rensselaer Polytechnic Institute\u2019s Hall of Fame"] | ["Scientific Review (Chair)", "Nominating and Corporate Governance", "Quality, Compliance, Manufacturing and Risk Management"] | 2026 |
Biography sourced from the proxy statement filing.
Dr. Zoon has served as a director since November 2016. Dr. Zoon is currently NIAID/NIH Scientist Emeritus, a position she has held since August 2016 where she has also had budget responsibility for a division of intramural research at National Institute of Allergy and Infectious Diseases ( NIAID ). Dr. Zoon is also on the Board of Directors of the International Biomedical Research Alliance. Dr. Zoon has been a member of the National Academy of Medicine since 2002 and was also a member of the Division on Earth and Life Studies Committee, National Research Council, from 2015 to 2020. In 2021, Dr. Zoon joined the non-profit organization, International Alliance for Biological Standardization, as a special advisor. She was also a Board member of the Food and Drug Administration ( FDA ) Alumni Association from 2017 to 2020. From April 2016 to June 2016, she was Interim Director of the new NIH Office of Research Support and Compliance. She was also Chief of the Cytokine Biology Section in the Division of Intramural Research, NIAID, NIH until July 2016, where she conducted research on human interferon alphas and developed a new cell therapy using IFNs and autologous monocytes and she is still collaborating with the National Cancer Institute ( NCI ) on a clinical trial for ovarian cancer. She was previously the Scientific Director and the Director of the Division of Intramural Research at NIAID from 2006 to August 2015 and was the Deputy Director for Planning and Development of the Division of Intramural Research at NIAID, from 2004 to 2006. Dr. Zoon served as the Principal Deputy Director of the Center for Cancer Research at the NCI from 2003 to 2004. She served as the Director of the Center for Biologics Evaluation and Research ( CBER ) where she managed the $350 million budget, FDA (from 1992 to 2003), and a member of the NIH Scientific Directors from 1992 to 2015. Dr. Zoon was the Director of the Division of Cytokine Biology in CBER, from 1988 to 1992. She studied the production and purification of human interferon at NIH from 1975 to 1980. She received her Ph.D. in biochemistry from the Johns Hopkins University and her B.S. degree, cum laude, in chemistry from Rensselaer Polytechnic Institute. Dr. Zoon was an associate editor of the Journal of Interferon Research. She was President of the International Society for Interferon and Cytokine Research from 2000 to 2001. She has served as a member of the World Health Organization s Expert Committee on Biological Standards for almost two decades. In 2019, Dr. Zoon was honored by Women s Inc. as one of the most influential corporate board directors. In 2021, Dr. Zoon was inducted into the Rensselaer Polytechnic Institute s Hall of Fame. Qualifications: We believe Dr. Zoon s financial acumen and expertise in regulatory matters and product development adds great depth and breadth to our Board of Directors.